DE60233038D1 - Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen - Google Patents

Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen

Info

Publication number
DE60233038D1
DE60233038D1 DE60233038T DE60233038T DE60233038D1 DE 60233038 D1 DE60233038 D1 DE 60233038D1 DE 60233038 T DE60233038 T DE 60233038T DE 60233038 T DE60233038 T DE 60233038T DE 60233038 D1 DE60233038 D1 DE 60233038D1
Authority
DE
Germany
Prior art keywords
approved
immunogenic compositions
measles virus
vaccine strain
virus vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233038T
Other languages
English (en)
Inventor
Frederic Tangy
Chantal Combredet
Valerie Labrousse-Najburg
Michel Brahic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29716946&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60233038(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE60233038D1 publication Critical patent/DE60233038D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/12—Mumps virus; Measles virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE60233038T 2002-06-20 2002-06-20 Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen Expired - Lifetime DE60233038D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02291551A EP1375512B1 (de) 2002-06-20 2002-06-20 Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen

Publications (1)

Publication Number Publication Date
DE60233038D1 true DE60233038D1 (de) 2009-09-03

Family

ID=29716946

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233038T Expired - Lifetime DE60233038D1 (de) 2002-06-20 2002-06-20 Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen

Country Status (15)

Country Link
US (3) US9005961B2 (de)
EP (5) EP1375512B1 (de)
KR (1) KR101227128B1 (de)
CN (1) CN100577683C (de)
AT (1) ATE437175T1 (de)
AU (1) AU2003266950A1 (de)
BR (1) BRPI0312173B8 (de)
CA (1) CA2489052C (de)
CY (1) CY1109506T1 (de)
DE (1) DE60233038D1 (de)
DK (2) DK1375512T3 (de)
ES (2) ES2330309T3 (de)
HK (1) HK1061568A1 (de)
PT (1) PT1375512E (de)
WO (1) WO2004000876A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (de) * 2000-10-26 2002-05-02 Genopoietic Synthetische Viren und ihre Verwendungen
EP1375512B1 (de) * 2002-06-20 2009-07-22 Institut Pasteur Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
EP1375670B1 (de) * 2002-06-20 2013-06-12 Institut Pasteur Rekombinante Masernviren, welche Epitope der Antigene von RNA-Viren exprimieren, sowie die Verwendung der rekombinanten Viren zur Herstellung von Impfstoffen
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
US20090004203A1 (en) * 2007-05-29 2009-01-01 Vical Incorporated Methods of treating measles infectious disease in mammals
KR101718497B1 (ko) * 2007-11-26 2017-03-22 런던 스쿨 오브 하이진 앤 트로피컬 메디신 레오바이러스과 바이러스의 백신용 바이러스 균주를 제조하는 방법
EP2085479A1 (de) * 2008-01-31 2009-08-05 Institut Pasteur Reverse Genetik von Negativstrang-RNA-Viren in Hefe
EP2420242A1 (de) 2010-08-20 2012-02-22 Lauer, Ulrich M. Onkolytisches Masernvirus
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
EP2712871A1 (de) 2012-09-27 2014-04-02 Institut Pasteur Rekombinantes Masernvirus zur Expression von Chikungunya-Virus-Polypeptiden und deren Anwendungen
EP2759301A1 (de) 2013-01-24 2014-07-30 Institut Pasteur Verwendung eines genetisch modifizierten infektiösen Masernvirus mit erhöhten pro-apoptotischen Eigenschaften (MVDeltaC-Virus)
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EP2959915A1 (de) 2014-06-23 2015-12-30 Institut Pasteur Chimäres Dengue-Virus-Polyepitop aus Fragmenten nichtstruktureller Proteine und deren Verbindung in einer immunogenen Zusammensetzung gegen Dengue-Virus-Infektion
EP3103474A1 (de) 2015-06-12 2016-12-14 Institut Pasteur Lebendes rekombinantes masern-m2-virus und dessen verwendung bei auslösung von immunität gegen influenzaviren
EP3184119A1 (de) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatografiebasierte reinigungsstrategien für viren auf basis eines maserngerüsts
JP6949468B2 (ja) * 2016-10-17 2021-10-13 ルプレヒト−カールス−ウニベルジテート ハイデルベルク 腫瘍抗原をコードする麻疹ウイルス
EP3622078A1 (de) * 2017-05-09 2020-03-18 Invectys Rekombinanter masernimpfstoff mit htert-expression
EP3412307A1 (de) 2017-06-07 2018-12-12 Institut Pasteur Zika-virus-proteine zur expression eines rekombinanten masernvirus und deren anwendungen
KR20200090186A (ko) 2017-11-09 2020-07-28 앵스티띠 파스퇴르 비-구조 단백질들을 포함하는 지카 바이러스 키메라 폴리에피토프 및 이의 면역원성 조성물로의 용도
SG11202004899SA (en) * 2017-12-21 2020-06-29 Pasteur Institut Lassa vaccine
CN111218475A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种拯救麻疹Schwarz/Moraten疫苗株的***和方法
EP3865180A1 (de) * 2020-02-13 2021-08-18 Institut Pasteur Lebende rekombinante masernviren, die coronavirus-antigene exprimieren, verwendung davon zur erzeugung von immunität gegen coronaviren
BR112022015764A2 (pt) * 2020-02-13 2022-10-11 Pasteur Institut Construções de ácido nucleico, vetores, vírus do sarampo, composições imunogênicas, processos para recuperar o vírus do sarampo, moléculas de ácido nucleico, polipeptídeos, proteínas recombinantes, usos in vitro de um antígeno, métodos para tratar ou prevenir uma infecção e para induzir uma resposta imune protetora
EP3936517A1 (de) 2020-07-08 2022-01-12 Institut Pasteur Verbesserter masernvirusimpfstoffvektor basierend auf mehreren zusätzlichen tandemtranskriptionseinheiten
US20240093233A1 (en) 2021-01-13 2024-03-21 Viroxis Measles-hiv or measles-htlv vaccine
CN113293148B (zh) * 2021-03-10 2022-10-25 上海青赛生物科技有限公司 一种h基因替换的嵌合麻疹减毒株的构建
EP4310186A1 (de) * 2021-03-15 2024-01-24 Misako Yoneda Rekombinantes masernvirus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
JP3045581B2 (ja) 1991-10-14 2000-05-29 社団法人北里研究所 麻疹ワクチンウイルス株同定方法
DK0780475T4 (da) * 1995-08-09 2006-10-23 Schweiz Serum & Impfinst Fremgangsmåde til fremstilling af infektiöse negativ-streng RNA-virus
CN1232504A (zh) * 1996-09-27 1999-10-20 美国氰胺公司 在单链负义病毒目病毒内引起减毒的3'基因组启动子区和聚合酶基因中的突变
EP0977587B1 (de) 1997-02-28 2005-06-15 Acambis Inc. Chimäre impfstoffe gegen flaviviren
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
CN1600852A (zh) * 1998-03-26 2005-03-30 惠氏控股有限公司 引起麻疹病毒或人呼吸道合胞病毒亚组b减毒的突变
WO1999063064A1 (en) * 1998-06-03 1999-12-09 American Cyanamid Company Novel methods for rescue of rna viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
EP1218499A2 (de) 1999-08-02 2002-07-03 Wyeth Rückgewinnung von mumps virus aus cdns
KR100862758B1 (ko) * 2000-04-28 2008-10-13 세인트 쥬드 칠드런즈 리써치 호스피탈 감염성 인플루엔자 바이러스 생성용 ｄｎａ 트랜스펙션시스템
EP1375670B1 (de) 2002-06-20 2013-06-12 Institut Pasteur Rekombinante Masernviren, welche Epitope der Antigene von RNA-Viren exprimieren, sowie die Verwendung der rekombinanten Viren zur Herstellung von Impfstoffen
EP1375512B1 (de) * 2002-06-20 2009-07-22 Institut Pasteur Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
US9623098B2 (en) * 2008-05-26 2017-04-18 Cadila Healthcare Limited Combined measles-human papilloma vaccine
EP2818175B1 (de) * 2009-05-05 2018-11-21 Cadila Healthcare Limited Kombinierter Impfstoff gegen Masern und Malaria

Also Published As

Publication number Publication date
CN1662553A (zh) 2005-08-31
ATE437175T1 (de) 2009-08-15
CA2489052C (en) 2014-07-29
KR20050058288A (ko) 2005-06-16
US20130296541A1 (en) 2013-11-07
AU2003266950A8 (en) 2004-01-06
EP2065393A1 (de) 2009-06-03
ES2330309T3 (es) 2009-12-09
US9701944B2 (en) 2017-07-11
US9005925B2 (en) 2015-04-14
DK1375512T3 (da) 2009-10-26
EP1375512A1 (de) 2004-01-02
EP2311853A1 (de) 2011-04-20
DK2311853T3 (en) 2018-04-16
CA2489052A1 (en) 2003-12-31
CY1109506T1 (el) 2014-08-13
ES2663224T3 (es) 2018-04-11
US20050227224A1 (en) 2005-10-13
EP1375512B1 (de) 2009-07-22
EP2110382A1 (de) 2009-10-21
HK1061568A1 (en) 2004-09-24
US9005961B2 (en) 2015-04-14
EP2311853B1 (de) 2017-12-27
KR101227128B1 (ko) 2013-01-29
WO2004000876A8 (en) 2005-03-03
BRPI0312173B8 (pt) 2021-05-25
WO2004000876A1 (en) 2003-12-31
CN100577683C (zh) 2010-01-06
BR0312173A (pt) 2005-04-05
PT1375512E (pt) 2009-09-23
EP1513872A1 (de) 2005-03-16
US20150275184A1 (en) 2015-10-01
AU2003266950A1 (en) 2004-01-06
BRPI0312173B1 (pt) 2019-05-07

Similar Documents

Publication Publication Date Title
DE60233038D1 (de) Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
NL300897I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
MA30581B1 (fr) Vaccin viral recombinant
DK1211318T3 (da) Paramyxovira omfattende en modificeret transkriptionsstartsekvens
ATE430207T1 (de) Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
ATE419369T1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
DK1373301T3 (da) Reducering af immunogeniciteten af fusionsproteiner
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
MXPA01003557A (es) Secuencias genomicas de neisseria y metodos para su uso.
DE602004020189D1 (de) Adjuvante influenza-vakzine
NO20082149L (no) Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
ATE521621T1 (de) Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
EA200600403A1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
ATE420191T1 (de) Promotoren zur expression im modifizierten vacciniavirus ankara
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
ATE420658T1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
DK1383796T3 (da) Neurovirulent stamme af viruset West Nile og anvendelser heraf
DE60229966D1 (de) Diabetesmodell
ATE447008T1 (de) Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon
JP2006524032A5 (de)

Legal Events

Date Code Title Description
8363 Opposition against the patent